Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SGX945, SGX942
Dusquetide · 3 trials · 3 indications
To assess the efficacy of SGX942 compared to placebo in decreasing the duration of severe oral mucositis (SOM; defined as World Health Organization \[WHO\] Grade ≥3). Duration of SOM is defined as the number of days from the onset of SOM until resolution of SOM. OM is evaluated using the published WHO OM grading scale that uses a scale of 0 to 4, with SOM defined as a score ≥3.
The number of oral ulcers were counted at baseline and each visit during the treatment period.
The number of genital ulcers will be counted at baseline and each visit during the treatment period.
| Arm | Type | Description |
|---|---|---|
| SGX942 | EXPERIMENTAL | Patients are randomized 1:1 active/placebo. |
| Placebo | PLACEBO_COMPARATOR | Patients are randomized 1:1 active/placebo. |
| SGX945 | EXPERIMENTAL | This is an open-label study and all participants will receive SGX945. |
| Name | Type | Description |
|---|---|---|
| SGX942 | DRUG | 1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends. |
| Placebo | DRUG | Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug. |
| Dusquetide | DRUG | 1.5 mg/mL dusquetide administered as a 4 minute IV infusion, twice per week for 4 weeks |
Inclusion Criteria: * Biopsy-proven squamous cell carcinoma of the oral cavity or oropharynx without distant organ metastases * Scheduled to receive cisplatin chemotherapy of 80-100 mg/m² * Scheduled to receive a continuous course of fractionated, conventional external beam with a cumulative radiat...
Top 20 of 30 competitors
Dusquetide is being developed for the treatment of Behçet Disease, an inflammatory condition. It is an investigational small molecule studied by Soligenix, Inc. in a Phase 2 clinical trial. It has not been approved for commercial use, and its study in Behçet Disease remains at the clinical development stage.
Dusquetide is being developed by Soligenix, Inc., a biopharmaceutical company that trades under the ticker symbol SNGX. Soligenix sponsored the Phase 2 clinical trial evaluating Dusquetide in patients with Behçet Disease.
Dusquetide is in Phase 2 clinical development for Behçet Disease. The completed Phase 2 trial, NCT06386744, enrolled 8 participants. Dusquetide is investigational and has not been approved by the FDA for any indication.
Dusquetide has been studied in one clinical trial, NCT06386744, titled "Dusquetide for the Treatment of Behcet's Disease." This Phase 2 trial was completed and enrolled 8 participants in Turkey. It was an uncontrolled study without randomization or double-blinding, and participants were 18 years or older.
Dusquetide is a small molecule in the peptide class, often referred to by the suffix -tide. It is being evaluated for its activity in Behçet Disease, an immune-mediated inflammatory condition. Its precise molecular target has not been publicly characterized in the available clinical data.